Remdesivir Completed Phase 3 Trials for Coronavirus Disease 2019 (COVID‑19) Treatment

Indications	Status	Purpose	Phase
DBCOND0129755 (Coronavirus Disease 2019 (COVID‑19))	Completed	Treatment	3

clinicaltrials.gov Identifier	Title	Drugs
NCT04593940	Immune Modulators for Treating COVID-19	Abatacept (DB01281) Cenicriviroc (DB11758) Infliximab (DB00065) Remdesivir (DB14761)
NCT04492475	Adaptive COVID-19 Treatment Trial 3 (ACTT-3)	Interferon beta-1a (DB00060) Remdesivir (DB14761)
NCT04401579	Adaptive COVID-19 Treatment Trial 2 (ACTT-2)	Baricitinib (DB11817) Remdesivir (DB14761)
NCT04280705	Adaptive COVID-19 Treatment Trial (ACTT)	Remdesivir (DB14761)
NCT04640168	Adaptive COVID-19 Treatment Trial 4 (ACTT-4)	Baricitinib (DB11817) Dexamethasone (DB01234) Remdesivir (DB14761)
NCT05185284	Randomized Multicenter Study on the Efficacy and Safety of Favipiravir for Parenteral Administration Compared to Standard of Care in Hospitalized Patients With COVID-19	Favipiravir (DB12466) Remdesivir (DB14761)
NCT04853901	Remdesivir Efficacy In Management Of COVID-19 Patients	Hydroxychloroquine (DB01611) Remdesivir (DB14761)
NCT04292730	Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment	Remdesivir (DB14761)
NCT04292899	Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19)	Remdesivir (DB14761)